Company intelligence
NeoGenomics Laboratories
Answers are in our DNA™
About NeoGenomics Laboratories
Our vision: A world where every cancer treatment decision is as personal as the patient. Our mission: We take cancer personally. We partner with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes -- through a comprehensive oncology portfolio and an unwavering commitment to excellence powered by a team of dedicated experts.
Verified activity
Signals from NeoGenomics Laboratories
9 published signals
Products & Services
NeoGenomics Laboratories launched Neo Comprehensive® for Myeloid Disorders testing, offering a single test for DNA and RNA alterations in a complete genomic view.
Reported by NeoGenomics Laboratories
Products & Services
NeoGenomics Laboratories launched PTEN IHC CDx as part of PanTracer Pro, pairing IHC-based PTEN deficiency identification with comprehensive genomic profiling.
Reported by NeoGenomics Laboratories
Presence & Recognition
NeoGenomics Laboratories presented research on AI-based detection and scoring of TROP2 expression in IHC-stained NSCLC specimens at AACR 2026, along with AI applications for automated phenotyping of multiplex immunofluorescence data.
Reported by Halit Kolenovic, MBA
People
NeoGenomics Laboratories is hiring two positions for the Product Marketing Team: one as a Director leading strategy across the portfolio and another as a Marketing Manager owning MRD in oncology.
Reported by Christina Reita
Products & Services
NeoGenomics Laboratories released the AML NanoMRD™ solution, a validated, off-the-shelf solution designed for low sample input and consistent deployment across clinical studies.
Reported by NeoGenomics Laboratories
Research & Knowledge
NeoGenomics Laboratories expanded the coverage of MolDX for RaDaR® ST and its role in immunotherapy monitoring for late-stage solid tumors.
Reported by Chris McCarthy
Research & Knowledge
NeoGenomics Laboratories reported two Roche companion-diagnostic approvals for Jazz Pharmaceuticals' Ziihera (zanidatamab) in HER2-positive gastroesophageal cancer, expanding the IHC assay to cover gastric, gastroesophageal junction, and esophageal adenocarcinoma and the ISH assay to cover HER2 testing.
Reported by David S. Brooks
Legal & Regulatory
NeoGenomics Laboratories expanded Medicare coverage for RaDaR® ST to provide ctDNA-based monitoring of immunotherapy response.
Reported by Jared Townsend, PhD
Products & Services
NeoGenomics Laboratories delivered improved turnaround times for Neo Comprehensive® Heme Cancers and Neo Comprehensive® Myeloid Disorders tests, with a TAT of 8–11 days.
Reported by Warren Stone, MBA